Smirnoff, Guinness Parent Diageo Talks About Adverse Tariffs Impact
Diageo plc (NYSE:DEO) shares are trading lower on Monday after the company reported a third-quarter fiscal 2025 trading update that showed steady growth in organic net sales and progress on its operational transformation efforts.
The maker of Smirnoff and Guinness posted $4.4 billion in net sales for the quarter ended March 31, marking a 2.9% increase year-over-year. Organic net sales rose 5.9%, driven by stronger pricing and shipment volumes.
The company's performance in the third quarter benefited from favorable phasing, which is estimated to have contributed approximately 4% to the group's organic net sales growth. This positive impact was primarily observed in North America, with a lesser contribution from the Latin America and Caribbean region. It is anticipated that this favorable phasing will reverse in the fourth quarter.Diageo reported a 6% organic net sales growth in North America, primarily driven by strong shipment growth in U.S. Spirits. While U.S. Spirits experienced strong shipment growth, Diageo noted that the overall U.S. Spirits category was softer.
U.S. Spirits organic net sales were up 7%. The gain was supported by restocking and import pull-forwards in anticipation of new tariffs.
Latin America and the Caribbean delivered a 29% organic sales jump, rebounding from last year's inventory correction and buoyed by improved consumer sentiment in Brazil and Mexico.
In contrast, Europe saw flat growth as solid momentum in Guinness was offset by continued softness in spirits. Asia Pacific posted modest gains, mainly due to easier year-ago comparisons, while Africa recorded 10% organic growth, fueled by strong demand in East Africa and Ghana.
Chief Executive Debra Crew said the company is 'on track' to meet its fiscal 2025 outlook despite macroeconomic uncertainty and new tariffs on U.K. and EU imports into the U.S. Diageo expects the total impact of these tariffs to reach approximately $150 million annually, though it aims to mitigate roughly half of that through cost controls and pricing strategies.
As part of its newly launched 'Accelerate' initiative, Diageo plans to generate approximately $3 billion in free cash flow annually starting in fiscal 2026. The program also includes a $500 million cost reduction plan over three years and targets a reduction in leverage to 2.5–3.0x net debt to EBITDA by fiscal 2028.
Diageo reaffirmed its fiscal 2025 guidance for the full year, expecting a sequential improvement in organic net sales growth during the second half. However, it anticipates a slight decline in organic operating profit year-over-year, in line with the first half, due in part to ongoing tariff pressures.
Capital expenditures for the year are expected to be near the upper end of the $1.3 to $1.5 billion range, and the company projects a slightly lower effective interest rate than the 4.3% recorded in fiscal 2024. The full-year results will also introduce a revised tax reporting method.
Related ETFs: Consumer Staples Select Sector SPDR Fund (NYSE:XLP), iShares Global Consumer Staples ETF (NYSE:KXI).
Price Action: DEO shares are trading lower by 1.02% to $113.88 at last check Monday.
Image by Evgeniyqw via Shutterstock
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Smirnoff, Guinness Parent Diageo Talks About Adverse Tariffs Impact originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Stablecoin Issuer Circle Surges 168% in NYSE Debut After IPO Tops Price Expectations
Shares of Circle Internet Group (NYSE:CRCL) jumped 168% on Thursday following its initial public offering, which raised nearly $1.1 billion for the stablecoin firm and its selling shareholders. The stock debuted at $69 on the New York Stock Exchange, well above its IPO price of $31, and at one point hit a high of $103.75. Circle Internet Group (NYSE:CRCL) set its IPO price late Wednesday, significantly above both the revised $27–$28 range earlier in the week and the initial $24–$26 estimate from last week, giving the company a valuation of around $6.8 billion before trading began. By the end of the day, trading volume hit approximately 46 million shares, well above the number of publicly available shares. CEO Jeremy Allaire made the following statement on CNBC's 'Money Movers' on Thursday: 'To realize our vision, we needed to forge relationships with governments, we needed to work with policymakers … because if you want this to work for mainstream, it's got to work in mainstream society and you need to have those rules of the road. We've been one of the most licensed, regulated, compliant, transparent companies in the entire history of this industry, and that's served us well.' Allaire co-founded Circle Internet Group (NYSE:CRCL) in 2013. Originally headquartered in Boston, the company began with a focus on consumer payment solutions, along with crypto wallet and exchange services. In 2015, it became the first company to secure the notoriously hard-to-get BitLicense from New York State. Earlier this year, Circle relocated its headquarters to New York. While we acknowledge the potential of CRCL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
HSBC Upgrades Dr. Reddy's Laboratories Limited (RDY) to Buy from Hold
On June 5, HSBC upgraded Dr. Reddy's Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from INR1,235, citing an optimistic outlook for the company in terms of earnings potential and solid market standing. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. HSBC's updated estimates for FY2026 to FY2028 take into account the shifting market tide for semaglutide and gRevlimid. The analysts are waiting for semaglutide to be introduced in Canada, Brazil, and India at the beginning of FY2027, which is a greater leap from their prior hypothesis of a launch only in Canada by Q4 of FY2026. The analysts revised their FY2026 sales figures for Dr. Reddy's Laboratories Limited (NYSE:RDY)'s gRevlimid, noting the growing competition. The adjustment includes a 5.1% decrease in the EPS estimate for FY2026, while the EPS forecast for FY2027 and FY2028 grew by 12% to 13%. According to HSBC analysts, the expected surge in semaglutide sales will strengthen Dr. Reddy's earnings. HSBC assigned a new price target for RDY's American Depositary Receipts (ADR) as well, raising it from $14.44 to $16.90. Dr. Reddy's Laboratories Limited (NYSE:RDY) is a global pharma company based in Hyderabad, India, that makes both branded and generic medicines for a wide range of health conditions. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. While we acknowledge the potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
UBS Upholds Buy Recommendation on Deckers Outdoor (DECK)
On June 5, UBS analysts maintained a Buy rating on Deckers Outdoor Corporation (NYSE:DECK) with a price target of $169. The analysts expect Decker's EPS to top market estimates over the coming year as sales projections increase for its Hoka brand. They also anticipate UGG to keep up its record as a major global casual footwear brand. A customer browsing a retail store, finding the perfect footwear for their casual outfits. The analysts were confident that Deckers Outdoor Corporation (NYSE:DECK) could deliver a low double-digit compound annual sales growth. They forecast that this growth could drive Deckers' forward PE ratio over 20x, compared to the present 16.7x. The $169 price target by UBS reflects a 60% upside for DECK. The stock has plummeted nearly 47% over the last six months, which signals a buying opportunity. After discussions with company management on June 4, the analysts were optimistic about Deckers Outdoor Corporation (NYSE:DECK)'s potential for growth. Despite the market showing caution with reference to the Hoka brand's capacity to sustain robust growth, UBS believes that DECK is perfectly tackling concerns about industry competition, evolving fashion trends, and dependence on Clifton and Bondi franchises. The analysts see double-digit revenue growth for Hoka in the next few years. Deckers Outdoor Corporation (NYSE:DECK) designs and markets premium footwear and apparel worldwide with brands like UGG and HOKA. The company was established in 1973 and is headquartered in Goleta, California. While we acknowledge the potential of DECK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None. Sign in to access your portfolio